Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Stoke Therapeutics, Inc. STOK

Set alert

Price alert · STOK

All alert types
26.68 USD +0.20 +0.76%

As of Nov 3, 9:35 AM ET

Bid
26.60 × 2
Ask
27.01 × 2
26.63 Day range 27.00
20.32 52-week range 40.22
YTD
-15.94%
1 year
+2.22%
Open
26.84
Prev close
26.48
Mkt cap
1.73B
Vol
14.52K
Avg vol
1.02M
EPS
-3.81
P/E
0.00
Div yield
0.00%
More statistics
Low
26.63
High
27.00
Forward P/E
-7.03
Beta
1.38
Short ratio
10.28
Inst. own
124.91%
Dividend
0.00
Ex-div date
Earnings
Mar 15, 2027
50-d avg
27.43
200-d avg
30.92
1y target
46.38

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 4, 2026Rating: Chardan Capital · Buy → Buy
  • Aug 4, 2026Rating: Canaccord Genuity · Buy → Buy
  • Aug 4, 2026Rating: Wedbush · Outperform → Outperform
  • Aug 4, 2026Rating: Guggenheim · Buy → Buy
  • Oct 29, 2026Earnings: -1.08; estimate -0.92914; surprise -16.24%
Signals (12)
NameDateAgo
SMA: BullishOct 27, 20261 week ago
SMA: BearishOct 21, 20261 week ago
SMA: BullishOct 20, 20262 weeks ago
MACD: Buy SignalOct 15, 20262 weeks ago
RSI: OversoldOct 13, 20263 weeks ago
RSI: OversoldOct 7, 20263 weeks ago
RSI: OversoldSep 25, 20261 month ago
SMA: BearishSep 1, 20262 months ago
SMA: BearishAug 31, 20262 months ago
MACD: Sell SignalAug 28, 20262 months ago
SMA: BullishAug 4, 20263 months ago
SMA: BullishAug 4, 20263 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 46.38 +73.9% upside
Target (low)
35.00
Target (mean)
46.38
Target (high)
60.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy12
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 14
  • 1 month ago 14
  • 2 months ago 14
  • 3 months ago 14

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

STOK analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.97033-1.30 – -0.70-0.97-0.0%7.33M+422.9%12
Next quarter-1.08-1.43 – -0.64-0.79-37.1%6.80M+9.2%6
Current year-4.05-4.29 – -3.94-0.12-3275.0%35.66M-80.7%6
Next year-3.73-5.00 – -2.55-4.05+7.9%47.15M+32.2%12

Upgrades and downgrades

The latest rating changes

STOK analyst upgrades and downgrades
DateFirmActionFromTo
Aug 4, 2026GuggenheimReiteratedBuyBuy
Aug 4, 2026WedbushMaintainedOutperformOutperform
Aug 4, 2026Canaccord GenuityMaintainedBuyBuy
Aug 4, 2026Chardan CapitalMaintainedBuyBuy
Jul 13, 2026Goldman SachsInitiated—Buy
May 11, 2026BTIGReiteratedBuyBuy
Mar 20, 2026Canaccord GenuityMaintainedBuyBuy
Mar 19, 2026BTIGReiteratedBuyBuy
Mar 18, 2026WedbushMaintainedOutperformOutperform
Mar 18, 2026Chardan CapitalMaintainedBuyBuy
Mar 17, 2026WedbushMaintainedOutperformOutperform
Mar 17, 2026NeedhamMaintainedBuyBuy
Feb 24, 2026Wolfe ResearchInitiated—Outperform
Jan 12, 2026WedbushMaintainedOutperformOutperform
Jan 5, 2026Chardan CapitalMaintainedBuyBuy
Jan 5, 2026Canaccord GenuityMaintainedBuyBuy
Dec 15, 2025HC Wainwright & Co.MaintainedBuyBuy
Nov 5, 2025Canaccord GenuityMaintainedBuyBuy
Nov 5, 2025WedbushMaintainedOutperformOutperform
Nov 5, 2025BTIGReiteratedBuyBuy
Nov 3, 2025JP MorganMaintainedNeutralNeutral
Oct 13, 2025BTIGMaintainedBuyBuy
Oct 10, 2025NeedhamMaintainedBuyBuy
Aug 13, 2025Chardan CapitalMaintainedBuyBuy
Aug 13, 2025WedbushMaintainedOutperformOutperform
Jul 18, 2025JefferiesInitiated—Buy
Jul 1, 2025NeedhamReiteratedBuyBuy
May 14, 2025HC Wainwright & Co.MaintainedBuyBuy
Apr 9, 2025NeedhamReiteratedBuyBuy
Mar 19, 2025HC Wainwright & Co.ReiteratedBuyBuy